Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2011

Open Access 01-12-2011 | Research article

Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

Authors: Elena P Calandre, Piedad Morillas-Arques, Rocío Molina-Barea, Carmen M Rodriguez-Lopez, Fernando Rico-Villademoros

Published in: BMC Musculoskeletal Disorders | Issue 1/2011

Login to get access

Abstract

Background

Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied. If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone. The aim of the present study was to assess the effectiveness of trazodone alone and in combination with pregabalin in the treatment of fibromyalgia.

Methods

This was an open-label uncontrolled study. Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period. Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory (BPI), the Short-Form Health Survey (SF-36), and the Patients' Global Improvement scale (PGI). Emergent adverse reactions were recorded. Data were analyzed with repeated measures one-way ANOVA and paired Student's t test.

Results

Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain. After pregabalin combination additional and significant improvements were seen on fibromyalgia severity, depression and pain interference with daily activities, and a decrease in bodily pain was also apparent. During the second phase of the study, only two patients dropped out due to side effects.

Conclusions

Trazodone significantly improved fibromyalgia severity and associated symptomatology. Its combination with pregabalin potentiated this improvement and the tolerability of the drugs in association was good.

Trial Registration

ClinicalTrials.gov: NCT00791739
Appendix
Available only for authorised users
Literature
1.
go back to reference Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA, OMERACT Fibromyalgia Working Group: Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009, 36: 2318-2329. 10.3899/jrheum.090367.CrossRefPubMedPubMedCentral Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA, OMERACT Fibromyalgia Working Group: Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009, 36: 2318-2329. 10.3899/jrheum.090367.CrossRefPubMedPubMedCentral
2.
go back to reference Mendelson WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005, 46: 469-476.CrossRef Mendelson WB: A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005, 46: 469-476.CrossRef
3.
go back to reference Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Artzeni F: Treatment strategy in fibromyalgia syndrome: where are we now?. Semin Arthritis Rheum. 2008, 37: 353-365. 10.1016/j.semarthrit.2007.08.008.CrossRefPubMed Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Artzeni F: Treatment strategy in fibromyalgia syndrome: where are we now?. Semin Arthritis Rheum. 2008, 37: 353-365. 10.1016/j.semarthrit.2007.08.008.CrossRefPubMed
4.
go back to reference Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L: An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007, 8: 27-10.1186/1471-2474-8-27.CrossRefPubMedPubMedCentral Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L: An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007, 8: 27-10.1186/1471-2474-8-27.CrossRefPubMedPubMedCentral
5.
go back to reference Stahl SM: Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums. 2009, 14: 536-546.PubMed Stahl SM: Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums. 2009, 14: 536-546.PubMed
6.
go back to reference Branco JC, Martini A, Paiva T: Treatment of sleep abnormalities and clinical complaints in fibromyalgia with trazodone. Arthritis Rheum. 1996, 39: S91- Branco JC, Martini A, Paiva T: Treatment of sleep abnormalities and clinical complaints in fibromyalgia with trazodone. Arthritis Rheum. 1996, 39: S91-
7.
go back to reference Clayton AH, West SG: Combination therapy for fibromyalgia. Curr Pharm Design. 2006, 12: 11-16. Clayton AH, West SG: Combination therapy for fibromyalgia. Curr Pharm Design. 2006, 12: 11-16.
8.
go back to reference Mease PJ, Seymour K: Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?. Curr Pain Headache Rep. 2008, 12: 399-405. 10.1007/s11916-008-0068-4.CrossRefPubMed Mease PJ, Seymour K: Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?. Curr Pain Headache Rep. 2008, 12: 399-405. 10.1007/s11916-008-0068-4.CrossRefPubMed
9.
go back to reference Hughes G, Martinez C, Myon E, Taïeb C, Wessely S: The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum. 2006, 54: 177-183. 10.1002/art.21545.CrossRefPubMed Hughes G, Martinez C, Myon E, Taïeb C, Wessely S: The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum. 2006, 54: 177-183. 10.1002/art.21545.CrossRefPubMed
10.
go back to reference Wolfe F, Claw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010, 62: 600-610. 10.1002/acr.20140.CrossRef Wolfe F, Claw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010, 62: 600-610. 10.1002/acr.20140.CrossRef
11.
go back to reference Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB: A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997, 40: 1560-1570. 10.1002/art.1780400904.CrossRefPubMed Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB: A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997, 40: 1560-1570. 10.1002/art.1780400904.CrossRefPubMed
12.
go back to reference White KP, Nielson WR, Harth M, Ostbye T, Speechley M: Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002, 47: 260-265. 10.1002/art.10400.CrossRefPubMed White KP, Nielson WR, Harth M, Ostbye T, Speechley M: Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002, 47: 260-265. 10.1002/art.10400.CrossRefPubMed
14.
go back to reference Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, Rico-Villademoros F, Calandre EP: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010, 11: 204-10.1186/1471-2474-11-204.CrossRefPubMedPubMedCentral Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, Rico-Villademoros F, Calandre EP: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010, 11: 204-10.1186/1471-2474-11-204.CrossRefPubMedPubMedCentral
15.
go back to reference Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardieri C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990, 33: 160-172. 10.1002/art.1780330203.CrossRefPubMed Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardieri C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990, 33: 160-172. 10.1002/art.1780330203.CrossRefPubMed
16.
go back to reference Rivera J, González T: The Fibromyalgia Impact Questionnaire: A validated spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004, 22: 554-460.PubMed Rivera J, González T: The Fibromyalgia Impact Questionnaire: A validated spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004, 22: 554-460.PubMed
17.
go back to reference Royuela A, Macías JA: Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño. 1997, 9: 81-94. Royuela A, Macías JA: Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño. 1997, 9: 81-94.
18.
go back to reference Vazquez C, Sanz J: Fiabilidad y valores normales de la versión española del inventario para la depresión de Beck de 1978. Clin Salud. 1997, 8: 403-422. Vazquez C, Sanz J: Fiabilidad y valores normales de la versión española del inventario para la depresión de Beck de 1978. Clin Salud. 1997, 8: 403-422.
19.
go back to reference Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I: Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 2003, 107: 216-221. 10.1034/j.1600-0447.2003.00062.x.CrossRefPubMed Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I: Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 2003, 107: 216-221. 10.1034/j.1600-0447.2003.00062.x.CrossRefPubMed
20.
go back to reference Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS, Grupo Vesbpi: Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc). 2003, 120: 52-59. 10.1157/13042265.CrossRef Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS, Grupo Vesbpi: Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc). 2003, 120: 52-59. 10.1157/13042265.CrossRef
21.
go back to reference Alonso J, Prieto L, Antó JM: The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc). 1995, 104: 771-776. Alonso J, Prieto L, Antó JM: The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc). 1995, 104: 771-776.
22.
go back to reference Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki RA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008, 9: 105-121. 10.1016/j.jpain.2007.09.005.CrossRefPubMed Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki RA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008, 9: 105-121. 10.1016/j.jpain.2007.09.005.CrossRefPubMed
23.
go back to reference Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U, Pregabalin 1008-105 Study group: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005, 52: 1264-1273. 10.1002/art.20983.CrossRefPubMed Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U, Pregabalin 1008-105 Study group: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005, 52: 1264-1273. 10.1002/art.20983.CrossRefPubMed
24.
go back to reference Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U: A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008, 35: 502-514.PubMed Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U: A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008, 35: 502-514.PubMed
25.
go back to reference Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyiline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheumn. 1986, 29: 1371-1377. 10.1002/art.1780291110.CrossRef Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyiline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheumn. 1986, 29: 1371-1377. 10.1002/art.1780291110.CrossRef
26.
go back to reference Fossaluza V, De Vita S: Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharm Res. 1992, 12: 99-102. Fossaluza V, De Vita S: Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharm Res. 1992, 12: 99-102.
27.
go back to reference Cantini F, Bellandi F, Niccoli L, Di Munno O: Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia. Minerva Med. 1994, 85: 97-100.PubMed Cantini F, Bellandi F, Niccoli L, Di Munno O: Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia. Minerva Med. 1994, 85: 97-100.PubMed
28.
go back to reference Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996, 39: 1852-1859. 10.1002/art.1780391111.CrossRefPubMed Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996, 39: 1852-1859. 10.1002/art.1780391111.CrossRefPubMed
29.
go back to reference Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Rico-Villademoros F, Hidalgo J: Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label prospective study. Pharmacopsychiatry. 2007, 40: 58-71. 10.1055/s-2007-970143.CrossRef Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Rico-Villademoros F, Hidalgo J: Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label prospective study. Pharmacopsychiatry. 2007, 40: 58-71. 10.1055/s-2007-970143.CrossRef
30.
go back to reference Kim SH, Song J, Mun H, Park KU: Effect of the combined use of tramadol and milnacipran on pain threshold on an animal model of fibromyalgia. Korean J Intern Med. 2009, 24: 139-142. 10.3904/kjim.2009.24.2.139.CrossRefPubMedPubMedCentral Kim SH, Song J, Mun H, Park KU: Effect of the combined use of tramadol and milnacipran on pain threshold on an animal model of fibromyalgia. Korean J Intern Med. 2009, 24: 139-142. 10.3904/kjim.2009.24.2.139.CrossRefPubMedPubMedCentral
31.
go back to reference Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC: A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999, 21: 180-191. 10.1007/BF02908299.CrossRefPubMed Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC: A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999, 21: 180-191. 10.1007/BF02908299.CrossRefPubMed
Metadata
Title
Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study
Authors
Elena P Calandre
Piedad Morillas-Arques
Rocío Molina-Barea
Carmen M Rodriguez-Lopez
Fernando Rico-Villademoros
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2011
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-12-95

Other articles of this Issue 1/2011

BMC Musculoskeletal Disorders 1/2011 Go to the issue